ORDER A TEST Log In Contact Us
Hero Background

PROVIDERS /// ONCOLOGY

Creating more options for your patients

Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.

CONTACT us

A comprehensive solution for all of your precision oncology needs

  1. GENOMIC PROFILING

    We deliver a comprehensive view of your patients through our tissue and liquid DNA profiling, somatic and germline testing, tumor-normal matched profiling and RNA sequencing.

  2. ALGORITHMIC TESTS

    We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.
  3. CLINICAL TRIAL MATCHING

    We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.
  4. DIGITAL PATHOLOGY & AI

    We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.
  5. FINANCIAL ASSISTANCE

    We are committed to making our tests accessible for those in financial need. Most applicants who qualify pay no more than $100.
  6. TEMPUS ONE

    We bring our proprietary AI-enabled service platform to you in real-time, through our novel technology and online capabilities.
  7. TEMPUS+

    We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.
  8. EMR INTEGRATION

    We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.

Streamlining your workflow

One order. One platform. One financial assistance program.

Browse our FAQs

We have established relationships that span from community practices to more than 50% of all academic medical centers in the United States.

Open video in popup image description
Open video in popup image description
Working with the top hospitals in North America

In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients' lives.

Joseph K Hofmeister, MD, OhioHealth

Working with the top hospitals in North America

Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.

Megan Kruse, MD, Cleveland Clinic

  • 5K+

    oncologists rely on Tempus as their precision medicine partner

  • 15K+

    patients identified for potential enrollment into clinical trials

  • 5M+

    de-identified research records

  • 20+

    operational countries across North, Central, South America, Europe, Middle East, and Asia

Our Science

view all publications
  • UPCOMING WEBINAR:

    Operational Metrics for the ELAINE II Study Combining a Traditional Approach With A Just-in-Time Model

    This study demonstrates the success that Tempus’ TIME Trial Program had with Sermonix’s Elaine II trial for patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

    Read more
  • UPCOMING WEBINAR:

    Use Of Clinical RNA-Sequencing In the Detection of Actionable Fusions Compared To DNA-Sequencing Alone

    RNA-based, whole-exome sequencing provides a complementary method for fusion detection, and may improve the identification of actionable variants.

    Read more
  • UPCOMING WEBINAR:

    Dual Tissue and Plasma Testing Improves Detection of Actionable Variants in Patients With Solid Cancers

    Dual tissue and ctDNA testing, “dual testing”, improved identification of actionable variants compared with either modality alone.

    Read more
  • UPCOMING WEBINAR:

    Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities

    Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.

    Read more
  • UPCOMING WEBINAR:

    Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA

    Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.

    Read more
  • UPCOMING WEBINAR:

    Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines

    This study found that Tumor-normal (T/N) matched next-generation sequencing (NGS) has multiple advantages including enhanced variant classification and incidental germline variant discovery that may be missed with a guidelines-based approach.

    Read more

Featured News and Events

view all news
  • UPCOMING WEBINAR:

    Tempus at ESMO Congress 2022

    AI-driven Tempus Tumor Origin test demonstrates increased confidence in the therapeutic management of CUP patients.

    Read more
  • UPCOMING WEBINAR:

    Webinar: The Evolving Standards of Precision Medicine

    Implications of Tempus abstract findings from the 2022 ASCO® Annual Meeting

    Watch now
  • UPCOMING WEBINAR:

    Blog: Unlocking the Value of RNA Data

    The utility of whole transcriptome RNA sequencing now and in the future

    Read more
  • UPCOMING WEBINAR:

    Eric Lefkofsky joins the Washington Post’s “Chasing Cancer” series

    Tempus founder and CEO Eric Lefkofsky discusses the state of precision medicine with reporter Yasmeen Abutaleb.

    Read more
  • UPCOMING WEBINAR:

    Tempus introduces the DPYD predictive diagnostic test to its growing collection of algorithms

    The newest Tempus algorithmic predictive test assesses for relevant mutations in the DPYD gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies.

    Read more
  • UPCOMING WEBINAR:

    Tempus and Cedars-Sinai collaborate on a new precision medicine initiative

    As part of the collaboration, Cedars-Sinai is leveraging Tempus’ genomic sequencing tests and data structuring capabilities for a variety of clinical and research efforts.

    Read more

Validations and Resources

view all resources
  • UPCOMING WEBINAR:

    Tempus xT Validation

    Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.

    Read more
  • UPCOMING WEBINAR:

    Tempus xF Validation

    Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.

    Read more
  • UPCOMING WEBINAR:

    Standard Requisition Form

    We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.

    View here

Partnering with Tempus is investing in the future

Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.